Abstract
Background: Lipid nanoparticles have been studied mainly as a means of transporting and releasing drugs. A special emphasis has been placed on designing nanoparticles that improve the delivery of drugs with targets in the central nervous system.
Methods: The biomedical literature was searched for basic and clinical studies. The recent applications are described and related with their bioactivities. Results: The current review compiles data on the components and features of lipid nanoparticle systems as well as the necessary conditions for their selective action. As an example of their application, we present data from preclinical and clinical studies on lipid nanoparticles used as potent and efficient agents in the diagnosis and treatment of some neurodegenerative maladies, including Parkinson’s disease. Conclusion: Current evidence supports the application of lipid nanoparticles for designing drugs carriers for neurodegenerative diseases. Also, we have gathered data that suggests a role of drug-free lipid nanoparticles as neuroprotective or preventive agents during neurodegenerative processes.Keywords: Central nervous system, neurodegenerative disease, nanoparticles, nanoliposomes, drug delivery, Parkinson's disease.
Current Pharmaceutical Design
Title:Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Volume: 23 Issue: 21
Author(s): Segura-Uribe Julia J, Ciprés-Flores Fabiola Jimena, Farfán-García Eunice Dalet, Trujillo-Ferrara José Guadalupe and Soriano-Ursúa Marvin Antonio*
Affiliation:
- Departamento de Fisiología, Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, C.P. 11340, Ciudad de México,Mexico
Keywords: Central nervous system, neurodegenerative disease, nanoparticles, nanoliposomes, drug delivery, Parkinson's disease.
Abstract: Background: Lipid nanoparticles have been studied mainly as a means of transporting and releasing drugs. A special emphasis has been placed on designing nanoparticles that improve the delivery of drugs with targets in the central nervous system.
Methods: The biomedical literature was searched for basic and clinical studies. The recent applications are described and related with their bioactivities. Results: The current review compiles data on the components and features of lipid nanoparticle systems as well as the necessary conditions for their selective action. As an example of their application, we present data from preclinical and clinical studies on lipid nanoparticles used as potent and efficient agents in the diagnosis and treatment of some neurodegenerative maladies, including Parkinson’s disease. Conclusion: Current evidence supports the application of lipid nanoparticles for designing drugs carriers for neurodegenerative diseases. Also, we have gathered data that suggests a role of drug-free lipid nanoparticles as neuroprotective or preventive agents during neurodegenerative processes.Export Options
About this article
Cite this article as:
J Julia Segura-Uribe, Jimena Fabiola Ciprés-Flores, Dalet Eunice Farfán-García, Guadalupe José Trujillo-Ferrara and Antonio Marvin Soriano-Ursúa*, Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170301123504
DOI https://dx.doi.org/10.2174/1381612823666170301123504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and <i>In Vivo</i> from a Single Lentiviral Vector
Current Gene Therapy The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Performance of Feature Selection Methods
Current Genomics An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Cell-Based Assay System to Estimate the Effect of 125I Seeds on Cancer Cells: Effect of Osteopontin
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
Current Medicinal Chemistry DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry Chemical Consequences of Radioactive Decay and their Biological Implications
Current Radiopharmaceuticals Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Current Pharmaceutical Design DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry